IMMUNOe Research Center

Institution (Facility)

Homepage ROR

Also Known As

IMMUNOe Research Center

Publications

3.2K

Citations

Authors

Concepts

About

IMMUNOe Research Center is a facility institution in Centennial, United States known for medicine, immunology, and primary immunodeficiency.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	260
2	Immunology	2	2	196
3	Health Sciences	1	1	183
4	Neurology	1	1	183
5	Pharmacology	1	1	64

IMMUNOe Research Center

Publications

3.2K

Citations

Page 1

	Year	Citations
Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial Richard Dodel, Axel Rominger, Peter Bartenstein, The Lancet Neurology Geriatric NeurologyAlzheimer's DiseaseMedicineDementiaIntravenous Immunoglobulin	2013	183
Efficacy and Safety of a New 20% Immunoglobulin Preparation for Subcutaneous Administration, IgPro20, in Patients With Primary Immunodeficiency John B. Hagan, Mary Beth Fasano, Sheldon Spector, Journal of Clinical Immunology	2010	130
Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033 Jonathan Q. Tran, Jitesh Rana, Frederik Barkhof, Neurology Neuroimmunology & Neuroinflammation	2014	121
Pharmacokinetics of Subcutaneous IgPro20 in Patients with Primary Immunodeficiency Richard L. Wasserman, Isaac Melamed, Robert P. Nelson, Clinical Pharmacokinetics Primary ImmunodeficiencyTreatment And PreventionMedicinePharmacotherapyHiv	2011	64
Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America Daniel Suez, Mark R. Stein, Sudhir Gupta, Journal of Clinical Immunology	2016	62
Evaluation of the Cunningham Panel™ in pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS): Changes in antineuronal antibody titers parallel changes in patient symptoms Craig Shimasaki, Richard E. Frye, Rosario Rich Trifiletti, Journal of Neuroimmunology	2019	53
Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency Richard L. Wasserman, Isaac Melamed, Mark R. Stein, Journal of Clinical Immunology	2016	47
A pilot study of high‐dose intravenous immunoglobulin 5% for autism: Impact on autism spectrum and markers of neuroinflammation Isaac Melamed, Melinda Heffron, Alessandro Testori, Autism Research	2018	41
Recombinant Human Hyaluronidase Facilitated Subcutaneous Immunoglobulin Treatment in Pediatric Patients with Primary Immunodeficiencies: Long-Term Efficacy, Safety and Tolerability Richard L. Wasserman, Isaac Melamed, Lisa Kobrynski, Immunotherapy	2016	38
Anti-LINGO-1 has no detectable immunomodulatory effects in preclinical and phase 1 studies Ann Ranger, Soma Ray, Suzanne Szak, Neurology Neuroimmunology & Neuroinflammation	2017	30

Page 1